ACTINIUM PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | $0 |
| Gross Profit | — | — | — | — | — | — | — | $0 |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $17.1M | $17.7M | $17.8M | $13.5M | $12.3M | $3.1M | $3.4M | $323.8K |
| SG&A Expense | $6.7M | $9.2M | $9.0M | $11.3M | $10.2M | $3.5M | $4.5M | $3.0M |
| Operating Income | $-23.8M | $-26.9M | $-26.8M | $-24.8M | $-22.5M | $-6.6M | $-7.9M | $-3.3M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | $5.0K | $7.9K | $866 | $2.5K | $1.1M | $-175.1K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | $0 |
| Net Income | $-23.7M | $-26.6M | $-24.3M | $-21.0M | $-24.7M | $-10.8M | $-8.4M | $-3.4M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-0.22 | $-0.40 | $-0.50 | $-0.55 | $-0.90 | $-0.47 | $-7.58 | $-4.30 |
| EPS (Diluted) | $-0.22 | $-0.40 | $-0.50 | $-0.55 | $-0.90 | $-0.47 | $-7.58 | $-4.30 |
| Shares Outstanding (Basic) | 115.7M | 80.1M | 55.8M | 44.1M | 30.0M | 24.6M | 21.4M | 13.7M |
| Shares Outstanding (Diluted) | 115.7M | 80.1M | 55.8M | 44.1M | 30.0M | 24.6M | 21.4M | 13.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |